Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125004163 | 12500416 | 3 | F | 201605 | 20160912 | 20160627 | 20160915 | PER | US-PFIZER INC-2016309953 | PFIZER | 35.00 | YR | F | Y | 52.00000 | KG | 20160915 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125004163 | 12500416 | 1 | PS | VFEND | VORICONAZOLE | 1 | 50 MG TABLET, FIVE AT A TIME (250 MG TWICE A DAY) | Y | 21266 | 250 | MG | FILM-COATED TABLET | BID | ||||||
| 125004163 | 12500416 | 2 | SS | VFEND | VORICONAZOLE | 1 | 600 MG, DAILY | Y | 21266 | 600 | MG | FILM-COATED TABLET | |||||||
| 125004163 | 12500416 | 3 | SS | VFEND | VORICONAZOLE | 1 | 400 MG, DAILY | Y | 21266 | 400 | MG | FILM-COATED TABLET | |||||||
| 125004163 | 12500416 | 4 | SS | VFEND | VORICONAZOLE | 1 | 200 MG, 2X/DAY | Y | F10253830 | 21266 | 200 | MG | FILM-COATED TABLET | BID | |||||
| 125004163 | 12500416 | 5 | SS | VORICONAZOLE. | VORICONAZOLE | 1 | Intravenous (not otherwise specified) | UNK | U | 21267 | POWDER FOR SOLUTION FOR INFUSION | ||||||||
| 125004163 | 12500416 | 6 | C | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | Oral | 75 MG, ONE TIME A DAY, PILL | 0 | 75 | MG | QD | |||||||
| 125004163 | 12500416 | 7 | C | CLOPIDOGREL | CLOPIDOGREL BISULFATE | 1 | 0 | ||||||||||||
| 125004163 | 12500416 | 8 | C | METOPROLOL. | METOPROLOL | 1 | Oral | 25 MG, HALF A TABLET TWICE A DAY | 0 | TABLET | BID | ||||||||
| 125004163 | 12500416 | 9 | C | METOPROLOL. | METOPROLOL | 1 | 0 | TABLET | |||||||||||
| 125004163 | 12500416 | 10 | C | GABAPENTIN. | GABAPENTIN | 1 | Oral | 300 MG, THREE TIMES A DAY | 0 | 300 | MG | TID | |||||||
| 125004163 | 12500416 | 11 | C | ASPIRIN. | ASPIRIN | 1 | Oral | 81 MG, ONCE A DAY | 0 | 81 | MG | TABLET | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125004163 | 12500416 | 1 | Fungal endocarditis |
| 125004163 | 12500416 | 5 | Fungal endocarditis |
| 125004163 | 12500416 | 6 | Blood pressure abnormal |
| 125004163 | 12500416 | 7 | Anticoagulant therapy |
| 125004163 | 12500416 | 8 | Blood pressure abnormal |
| 125004163 | 12500416 | 9 | Anticoagulant therapy |
| 125004163 | 12500416 | 10 | Neuropathy peripheral |
| 125004163 | 12500416 | 11 | Anticoagulant therapy |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125004163 | 12500416 | Amnesia | |
| 125004163 | 12500416 | Dizziness | |
| 125004163 | 12500416 | Fatigue | |
| 125004163 | 12500416 | Somnolence | |
| 125004163 | 12500416 | Visual impairment |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125004163 | 12500416 | 1 | 20160422 | 0 | ||
| 125004163 | 12500416 | 2 | 2016 | 0 | ||
| 125004163 | 12500416 | 3 | 2016 | 0 | ||
| 125004163 | 12500416 | 4 | 20160418 | 0 | ||
| 125004163 | 12500416 | 5 | 201604 | 0 | ||
| 125004163 | 12500416 | 6 | 20160418 | 201607 | 0 | |
| 125004163 | 12500416 | 8 | 20160418 | 201607 | 0 | |
| 125004163 | 12500416 | 10 | 20160418 | 201607 | 0 | |
| 125004163 | 12500416 | 11 | 20160418 | 0 |